Montelukast in AD

 
   Lead Investigator:    Lawren VandeVrede
   Institution      :    University of California, San Francisco
   E-Mail           :    lawren.vandevrede@ucsf.edu
   Proposal ID      :    1162



   Proposal Description:
   Effect of montelukast usage on AD progression. Looking to determine if montelukast use in patients with AD is related to older age at presentation or delay in disease progression. I would like to examine a data set with all  patients taking montelukast and a matched control set of AD patients not taking monteklukast to determine if there is a difference in these two cohorts. I?m interested in clinical outcomes, e.g. age at diagnosis, disease severity, and progression to AD (if initially MCI). I plan to compare clinical measures, though if enough patients have CSF biomarkers, it would be interesting to compare effect on fluid biomarkers as well.